Sub menu

 

 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset for information on the evaluation of prescription medicines.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Sponsor

Topics

AusPAR Date

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

569 result(s) found, displaying 201 to 225

  • AusPAR: Brolucizumab (rbe)

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Brolucizumab (rbe)

  • AusPAR: Nivolumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Nivolumab

  • AusPAR: Brigatinib

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Brigatinib

  • AusPAR: Trastuzumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Trastuzumab

  • AusPAR: Lanadelumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Takhzyro

  • AusPAR: Mecasermin

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Mecasermin

  • AusPAR: Ceritinib

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Ceritinib

  • AusPAR: Bevacizumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Bevacizumab

  • AusPAR: Ceftazidime/Avibactam

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Ceftazidime/Avibactam

  • AusPAR: Acalabrutinib

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Acalabrutinib

  • AusPAR: Lorlatinib

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Lorlatinib

  • AusPAR: Mepolizumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Mepolizumab

  • AusPAR: Acalabrutinib

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Acalabrutinib

  • AusPAR: Idebenone

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Idebenone

  • AusPAR: Progesterone

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Progesterone

  • AusPAR: Romosozumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Romosozumab

  • AusPAR: Nivolumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Nivolumab

  • AusPAR: Risankizumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Risankizumab

  • AusPAR: Lacosamide

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Lacosamide

  • AusPAR: Fremanezumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Fremanezumab